ZDA
NBIX icon

Zweig-DiMenna Associates’s Neurocrine Biosciences NBIX Stock Holding History

Zweig-DiMenna Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-92,976
Closed -$1.46M – 305
2014
Q3 		$1.46M Sell
92,976
-32,024
-26% -$479K 0.06% 139
2014
Q2 		$1.85M Buy
+125,000
New +$1.76M 0.08% 127

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Zweig-DiMenna Associates's NBIX Position: Q4 2014 in Review

Zweig-DiMenna Associates sold out of Neurocrine Biosciences (NBIX) in Q4 2014, closing a stake of 92,976 shares — an estimated $1.46M sold.

Zweig-DiMenna Associates first reported a position in NBIX in Q2 2014 and held it in 2 quarters. The position peaked at $1.85M in Q2 2014. 133 funds tracked by Wall St. Rank hold NBIX as of Q4 2014.

  • Zweig-DiMenna Associates reported no remaining Neurocrine Biosciences position as of Q4 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 92,976 Neurocrine Biosciences shares in Q4 2014, an estimated $1.46M.
  • Zweig-DiMenna Associates first reported a position in Neurocrine Biosciences in Q2 2014 and held it in 2 quarters.
  • Zweig-DiMenna Associates's Neurocrine Biosciences position peaked at $1.85M in Q2 2014.
  • 133 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2014, filed 12 Feb 2015.